Remove Generic Medicine Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

The critical role of the generics sector during the pandemic

pharmaphorum

During this time, the role and responsibility of generics suppliers and manufacturers has been brought into stark perspective as one of the leading contributors in this industry-wide effort. The pandemic has further highlighted how research is not strictly limited to large, “innovator” pharmaceutical companies.

article thumbnail

CHMP meeting highlights: February 2024

European Pharmaceutical Review

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceutical companies developing medicines, change is also happening. Vaccines approved for public use require comprehensive RCTs to establish their safety and efficacy.

Packaging 143
article thumbnail

How could tariffs impact the pharmaceutical industry?

European Pharmaceutical Review

The US imports a substantial volume of APIs and finished medicines, many of which are essential for patient care, meaning these tariffs could have far-reaching implications. 1 Here, we explore the potential impact of tariffs on pharmaceutical supply chains, pricing, investment and industry strategy.